Vaccine Contract Manufacturing Market Analysis

Vaccine Contract Manufacturing Market Analysis

To get key market trends

  Download Free Sample

Based on vaccine type, the market is segmented into attenuated, inactivated, subunit-based, toxoid-based, and DNA-based. The attenuated segment held highest market share of 30.1% in 2023.

• The strong efficacy and the ability to induce both cellular and humoral immunity make attenuated vaccines a preferred choice for many infectious diseases, contributing to their dominant market share.

   

• These vaccines have a long history of successful use in preventing various diseases, including measles, mumps, rubella, polio, and yellow fever. Their proven track record has built significant trust and confidence among healthcare providers and the public.

   

• This established success facilitates regulatory approvals and widespread adoption, ensuring they remain a substantial part of vaccination programs globally.

   

Based on scale of operation, the vaccine contract manufacturing market is classified into commercial, clinical, and preclinical. The commercial segment dominated the market and was valued at USD 1.4 billion in 2023.

• Commercial-scale operations cater to the mass production needs of vaccines for widespread distribution and administration. Vaccines, such as those for influenza, measles, mumps, rubella, and hepatitis, require high volumes to meet global demand, driving the need for large-scale manufacturing capabilities.

   

• Companies operating at a commercial scale have extensive distribution networks and established relationships with healthcare providers, pharmacies, and government agencies worldwide. These networks facilitate efficient distribution and supply chain management, allowing vaccines to reach diverse populations effectively. Such aforementioned factors contribute to the highe market share of this segment.

Based on service, the vaccine contract manufacturing market is divided into fill-finish and bulk vaccines. The fill-finish segment accounted for 57.2% of market share and is anticipated to grow at 10.8% over the forecast period.

• The fill-finish segment commands high market share in the market due to its critical role in ensuring the proper dosage, sterility, and stability of vaccine products.

   

• By outsourcing fill-finish services, vaccine manufacturers can mitigate operational risks, achieve cost efficiencies, and focus on core competencies such as research, development, and marketing, thereby driving the dominance of the fill-finish segment in the market.

   

Based on product type, the vaccine contract manufacturing market is categorized into combination vaccine and single vaccine. The combination vaccine segment is projected to reach USD 3.7 billion by 2032.

• High growth of this segment can be attributed to factors such as its efficiency, convenience, cost savings, streamlined manufacturing process, regulatory support and market preference.

   

• Furthermore, these vaccines offer expanded protection against a broader range of infectious diseases, including those with overlapping target populations or epidemiological profiles. This comprehensive protection is particularly advantageous for populations with limited access to healthcare services or in regions where multiple diseases coexist, driving the demand for combination vaccines.

   

Based on application, the vaccine contract manufacturing market is divided into human and veterinary. The human segment dominated the market in 2023 and is predicted to reach USD 6.3 billion by the end of the forecast period.

• Vaccines against diseases such as influenza, measles, mumps, rubella, hepatitis, and human papillomavirus (HPV) are in high demand due to their widespread prevalence and potential health impacts. Consequently, there is a continuous need to produce vaccines to prevent and control these human diseases, driving the dominance of the human segment.

   

• Furthermore, initiatives such as the Expanded Program on Immunization (EPI) by the World Health Organization (WHO) prioritize the distribution and administration of human vaccines to vulnerable populations, underscoring their importance and driving demand for contract manufacturing services.

   

Based on end-user, the vaccine contract manufacturing market is classified into pharmaceutical & biotechnology companies and academic and research institutes. The pharmaceutical & biotechnology companies segment held majority of market share in 2023 and was valued at USD 2.2 billion.

• Factors such as high production capacity, lower costs, and access to specialized expertise, significantly increases the adoption of contract manufacturing services by pharmaceutical & biotechnology companies.

   

• Additionally, these companies invest significantly in R&D initiatives, including vaccine discovery, preclinical testing, and clinical trials. These investments drive innovation and the development of novel vaccine candidates, creating opportunities for contract manufacturing partnerships to scale up production and bring vaccines to market efficiently.

North America vaccine contract manufacturing market in 2023 was valued at USD 1.1 billion and is expected to experience growth at 10.8% of CAGR.

• North America boasts a well-developed pharmaceutical industry with numerous established pharmaceutical and biotech companies that specialize in vaccine research, development, and manufacturing, driving growth of the region.

   

• The region has one of the highest healthcare expenditures globally, reflecting significant investments in healthcare infrastructure, research, and development. The region's strong healthcare spending supports vaccine development and manufacturing activities, fostering a conducive environment for contract manufacturing partnerships and investments.

   

The U.S. vaccine contract manufacturing market is expected to reach USD 2.5 billion by the end of the analysis period.

• The U.S. boasts a robust pharmaceutical industry with numerous leading pharmaceutical and biotech companies that specialize in vaccine research, development, and manufacturing. Furthermore, FDA's rigorous oversight and expertise in vaccine regulation provide assurance to global markets, elevating the desirability of vaccines manufactured in the U.S.

   

• Moreover, the U.S. is a global leader in vaccine development and distribution, with several vaccines developed within its borders achieving widespread international use. This leadership status, coupled with the country's reputation for innovation and quality, enhances the competitiveness of U.S.-based vaccine manufacturers in the global market.

   

Germany held a considerable share in global vaccine contract manufacturing market.

• With leading companies specializing in vaccine research, development, and manufacturing, Germany benefits from advanced infrastructure, skilled workforce, and regulatory expertise, positioning it as a hub for vaccine production.

   

• Additionally, its central location facilitates global distribution networks, while strong government support and investments drive innovation and competitiveness in the industry. Overall, these factors contribute to Germany's significant presence in the market.

   

India vaccine contract manufacturing market is anticipated to witness growth at substantial growth rate during the forecast period.

• India offers cost-effective manufacturing solutions driven by lower labor and operational costs compared to Western countries, making it an attractive destination for pharmaceutical companies seeking affordable vaccine production options.

   

• Additionally, the country's well-educated workforce, particularly in areas such as bioprocessing, quality control, and regulatory compliance, enhances its capability to meet the demand for vaccine manufacturing services. Owing to these factors India's market is poised for substantial growth during the forecast period.